TNF and rheumatoid arthritis: In a randomized phase 3 trial, ORAL STEP by Burmester et al. investigated tofacitinib (tofacitinib at 5 mg or 10 mg twice per day—BID) in combination with MTX in patients with active RA with an inadequate response to TNF inhibitors [92].